On January 7, Shanghai Pharmaceutical Holding Subsidiary, XinAIA Bank, received the "Notice of Approval of Drug Supplemental Application" (Notice No. 2020B05358) issued by the State Drug Administration on cephalosporading capsules (hereinafter referred to as "the drug"), which is evaluated consistently by generic drugs.
cephalosporine capsules are mainly suitable for acute pharyngitis, tonsillitis, otitis media, bronchitis and pneumonia and other respiratory infections, genitourinary tract infections and skin soft tissue infections caused by sensitive bacteria.
the drug as an oral preparation and should not be used for serious infections, it was developed by the United States- and first marketed in Ireland in 1972.
January 2020, The New Asia Bank filed an application with the State Drug Administration for a consistent evaluation of the drug's generics.
date of this announcement, the company's consistent evaluation of the drug has invested about 5.98 million yuan in research and development costs.
as of this announcement date, the main manufacturers of the drug in China are Shanghai Shiguibao Pharmaceutical Co., Ltd., Yangzijiang Pharmaceutical Group Co., Ltd., Shandong Xinhua Pharmaceutical Co., Ltd.
IQVIA database, the purchase amount of the drug hospital in 2019 was RMB31.76 million.
2019, the drug will have sales of 8.24 million yuan.